Search results for "From ACP Journal Club"
Diagnostic performance of 5 FITs varied for detection of advanced colorectal neoplasia
The differences among the fecal immunochemical tests (FITs) in the cross-sectional study show that choice of FIT clearly matters and that FITs should not be considered interchangeable in screening programs for colorectal cancer, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/12/20/8.htm
20 Dec 2024
In patients receiving invasive ventilation, PPIs reduce upper GI bleeding but did not affect mortality at 90 d
An ACP Journal Club commentary said the results of the REVISE trial support the routine use of first-line proton-pump inhibitors (PPIs) for stress ulcer prophylaxis in high-risk, critically ill, ventilated patients but noted that the definition of “high risk” is uncertain.
https://gastroenterology.acponline.org/archives/2024/10/25/9.htm
25 Oct 2024
In active ulcerative colitis, risankizumab induced and maintained remission
An industry-funded study provided evidence that risankizumab can be considered a first-line or rescue therapy for moderate to severe ulcerative colitis, but with many medication options, cost may be a consideration, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/11/22/10.htm
22 Nov 2024
In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y
This was an interim analysis of an industry trial, and final results are needed to determine whether patients with nonalcoholic (or metabolic dysfunction-associated) steatohepatitis (NASH) show clinically meaningful benefits, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/06/28/11.htm
28 Jun 2024
A next-generation mt-sDNA test had 94% sensitivity for colorectal cancer and 91% specificity for advanced neoplasia
An ACP Journal Club commentary questioned whether multitarget stool DNA (mt-sDNA) is better than fecal immunochemical testing (FIT) or outperformed FIT because of a lower threshold for colonoscopy referral, recommending that the tests be compared at the same referral rate.
https://gastroenterology.acponline.org/archives/2024/09/27/8.htm
27 Sep 2024
In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo
An ACP Journal Club commentary said the high-quality randomized trial provides pragmatic guidance on amitriptyline dosing in patients with irritable bowel syndrome (IBS), as well as additional support for the drug as an option in primary care after first-line therapies fail.
https://gastroenterology.acponline.org/archives/2024/02/23/7.htm
23 Feb 2024
In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas
The results of the industry-funded study support the use of the multitarget stool RNA (mt-sRNA) test for screening, but better adherence will be needed, and it is unclear whether the new test offers any advantages over current stool DNA testing, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/02/23/6.htm
23 Feb 2024
In older patients receiving aspirin, H pylori eradication reduced hospitalization or death due to peptic ulcer bleeding at 2.5 y
Several limitations of the trial may affect the extent to which the results will change current practice of Helicobacter pylori eradication in patients receiving aspirin, especially older patients, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2023/04/21/6.htm
21 Apr 2023
In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements
Findings of the randomized trial bolster recommendations of diet manipulation and lifestyle modifications for chronic constipation syndromes, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/05/26/7.htm
26 May 2023
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
Given their overall safety and convenience, etrasimod and other oral sphingosine-1-phosphate receptor modulators can be considered as first-line therapy in clinically appropriate patients with ulcerative colitis (UC) who do not respond to 5-aminosalicylic acid medications, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/07/28/7.htm
28 Jul 2023